Drug
Salmeterol Xinafoate clinical trials
Also written Salmeterol and Serevent.
- studies test it
- 98
- open now
- 2
- in phase 3
- 17
- first study started
- 2000
Keep track of what changes. Save the Salmeterol Xinafoate studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Brand
Other names
Studies by the year they started
97 studies that test it; most in 2004 (10)
| Year | Studies |
|---|---|
| 2000 | 2 |
| 2002 | 2 |
| 2003 | 8 |
| 2004 | 10 |
| 2005 | 9 |
| 2006 | 10 |
| 2007 | 9 |
| 2008 | 10 |
| 2009 | 8 |
| 2010 | 3 |
| 2011 | 4 |
| 2012 | 3 |
| 2013 | 2 |
| 2014 | 7 |
| 2015 | 1 |
| 2016 | 2 |
| 2017 | 1 |
| 2018 | 2 |
| 2021 | 2 |
| 2024 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 13
- Phase 2
- 10
- Phase 3
- 17
- Phase 4
- 47
- No phase
- 11
What it is tested for
Each study’s main condition, where its own words name it.
- Asthma
- 39
Who runs them
Industry 66 · Other 32
GlaxoSmithKline (34) · Boehringer Ingelheim (12) · Teva Branded Pharmaceutical Products R&D, Inc. (4) · University of Dundee (3) · Novartis (3) · Novartis Pharmaceuticals (3) · Milton S. Hershey Medical Center (2) · University of Copenhagen (2)
Often tested with
Tested in the same studies.
Fluticasone (52) · Tiotropium (16) · Montelukast (7) · Formoterol (4) · Albuterol (4) · Indacaterol (4) · Budesonide (2) · Therapeutic Procedure (1)
Studies
Open first, then newest update. How each study uses Salmeterol Xinafoate is read from its arms, and is right about nine times in ten.
Testing it · 98
- A Study to Evaluate the Efficacy and Safety of QVM149 (Indacaterol Acetate / Glycopyrronium Bromide / Mometasone Furoate) Versus Salmeterol Xinafoate/Fluticasone Propionate in Children From 12 Years to Less Than 18 Years of Age With Asthma.RecruitingPhase 3Novartis PharmaceuticalsNCT05776927Written as Salmeterol Xinafoate / Fluticasone Propionate
- Salmeterol Effect on Exercise PerformanceRecruitingNot applicableUniversity of CopenhagenNCT06655012Written as Salmeterol
- Tiotropium/Salmeterol Inhalation Powder in COPDTerminatedPhase 3Boehringer IngelheimNCT00668772Written as Tiotropium/Salmeterol
- Sub-Sensitivity to Long-Acting Bronchodilators (LABA)CompletedNot applicableNational Jewish HealthNCT01117116Written as fluticasone propionate and salmeterol
- A Non- Inferiority Comparative Study Between Seretide® and Salmeterol/Fluticasone Eurofarma in Patients with AsthmaCompletedPhase 3Eurofarma Laboratorios S.A.NCT01202097Written as Salmeterol/Fluticasone
- A Multiple Dose Comparison of Tiotropium Inhalation Capsules and Salmeterol Inhalation Aerosol.CompletedPhase 3Boehringer IngelheimNCT00274560Written as Salmeterol
- Mechanisms of Adverse Effects of Long-Acting Beta-Agonists in AsthmaStatus unknownPhase 4Imperial College LondonNCT04503460Written as Salmeterol Xinafoate
- A 24-Week Treatment Study to Compare Standard of Care Versus the eMDPI DS in Participants 13 Years or Older With AsthmaCompletedPhase 4Teva Branded Pharmaceutical Products R&D, Inc.NCT04677959Written as Fluticasone propionate/salmeterol (FS)
- Efficacy and Safety Comparison of Tiotropium Daily + Salmeterol Daily or Twice Daily Versus Tiotropium Daily in Patients With COPDCompletedPhase 3Boehringer IngelheimNCT00662792Written as Tiotropium/Salmeterol (T+S_PE)
- Single Blind Cross-over Dose Response Study in Subjects of Two Inhalers of Salmeterol and Fluticasone PropionateCompletedPhase 1Kindeva Drug DeliveryNCT02232087Written as Salmeterol
- Montelukast Compared With Placebo and Salmeterol in Exercise-Induced Bronchoconstriction (0476-316)CompletedPhase 3Organon and CoNCT00245570Written as Comparator: Salmeterol
- Study to Determine the Pharmacokinetics and Tolerability of Fluticasone Propionate MDPI and Fluticasone Propionate/Salmeterol MDPI Compared to High Strength FLOVENT® DISKUS® and ADVAIR® DISKUS® in Patients With Persistent Asthma 12 Years of Age and OlderCompletedPhase 1Teva Branded Pharmaceutical Products R&D, Inc.NCT02437604Written as Treatment B: FS MDPI
- Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared With Fluticasone Propionate/Salmeterol Multidose Dry Powder InhalerCompletedPhase 3Teva Branded Pharmaceutical Products R&D, Inc.NCT02980133Written as Fluticasone Propionate/Salmeterol
- A Double Blind Open Label Comparator Study to Compare Treatments in 4 to 11 Year Old Patients With AsthmaCompletedPhase 1Teva Branded Pharmaceutical Products R&D, Inc.NCT02680561Written as Fluticasone propionate/salmeterol
- A 24-week Study to Compare Umeclidinium/Vilanterol (UMEC/VI), UMEC and Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)CompletedPhase 4GlaxoSmithKlineNCT03034915Written as Salmeterol 50 mcg via DISKUS
- Generation of Biological Samples Positive to Salmeterol for Anti-Doping ControlCompletedPhase 1Parc de Salut MarNCT04195867Written as Salmeterol Xinafoate
- Clinical Endpoint Bioequivalence Study of Fluticasone Propionate & Salmeterol Xinafoate (100μg/50μg)CompletedNot applicableWest-Ward PharmaceuticalNCT03535870Written as Fluticasone propionate/salmeterol
- Fluticasone and Salmeterol in Allergic RhinitisCompletedPhase 4University of DundeeNCT01388595Written as Salmeterol
- Fluticasone/Salmeterol (FP/SM) Versus Double the Dose Fluticasone (FP) in Patients With Mild to Moderate AsthmaCompletedPhase 4University of DundeeNCT00830505Written as fluticasone/salmeterol
- A Study Measuring Asthma Control In Pediatric And Adolescent Subjects Whose Asthma Is Worsened By Activity Or ExerciseCompletedPhase 4GlaxoSmithKlineNCT00118716Written as Fluticasone propionate/salmeterol
See all 98 studies that test Salmeterol Xinafoate →
Given in every arm · 11 — Salmeterol Xinafoate is usual care beside what is tested
- Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk AsthmaActive, not recruitingPhase 2SanofiNCT06676319Written as Fluticasone/Salmeterol
- Two Investigational Drugs in the Prevention of Airway Constriction Brought on by Exercise in Participants With Asthma (0476-911)CompletedPhase 3Organon and CoNCT00127166Written as Salmeterol xinafoate
- Evaluation of Dupilumab's Effects on Airway Inflammation in Patients With AsthmaCompletedPhase 2SanofiNCT02573233Written as fluticasone propionate and salmeterol
- A Phase III Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination (FDC) of Fluticasone Furoate+Umeclidinium Bromide+Vilanterol (FF/UMEC/VI) With the FDC of FF/VI in Subjects With Inadequately Controlled AsthmaCompletedPhase 3GlaxoSmithKlineNCT02924688Written as Fluticasone/salmeterol (FSC)
- Efficacy and Safety Study of GSK3772847 in Subjects With Moderately Severe AsthmaCompletedPhase 2GlaxoSmithKlineNCT03207243Written as Fluticasone propionate/salmeterol
- Asthma Clinical Research Network (ACRN) Trial - Tiotropium Bromide as an Alternative to Increased Inhaled Corticosteroid in Patients Inadequately Controlled on a Lower Dose of Inhaled Corticosteroid (TALC)CompletedPhase 3Milton S. Hershey Medical CenterNCT00565266Written as salmeterol xinafoate
- GSK159802 In Healthy Male Subjects And AsthmaticsCompletedPhase 1GlaxoSmithKlineNCT00364273Written as Salmeterol
- Study to Evaluate Efficacy/Safety of Combination Budesonide/Indacaterol vs Fluticasone/Salmeterol in Patients With COPDCompletedPhase 4Novartis PharmaceuticalsNCT02055352Written as Salmeterol
- Efficacy and Safety Comparison of Steroid or Placebo in Combination With Salmeterol and Tiotropium in COPDCompletedPhase 2Boehringer IngelheimNCT00535366Written as Salmeterol
- Investigation of the 24 Hour Forced Expiratory Flow in 1 Second (FEV1) Profile of a Single Dose of Indacaterol/Mometasone Delivered Via the TWISTHALER® Device in Adult Patients With Persistent AsthmaCompletedPhase 2NovartisNCT00557440Written as fluticasone propionate/salmeterol
- Evaluate Onset of Effect in Patients With Chronic Obstructive Pulmonary Disease (COPD) Treated With Formoterol Turbuhaler®CompletedPhase 2AstraZenecaNCT01048333Written as Salmeterol
As the comparator · 60 — what is tested is compared with Salmeterol Xinafoate
- ANTES B+ Clinical TrialTerminatedPhase 4Fundacio Privada Mon Clinic BarcelonaNCT06282861Written as Serevent
- Tiotropium/Salmeterol Inhalation Powder (Spiriva Handihaler and Salmeterol Polyethylene (PE) Capsule) in Chronic Obstructive Pulmonary Disease (COPD)TerminatedPhase 3Boehringer IngelheimNCT00662740Written as Salmeterol
- Evaluating Long Acting Beta Agonists Used to Treat Asthma Among Those With Either Arg/Arg or Gly/Gly GenotypesCompletedNot applicableColumbia UniversityNCT00521222Written as Fluticasone with salmeterol
- Study to Compare QVM149 and Free Triple Combination of Salmeterol/Fluticasone + TiotropiumCompletedPhase 3Novartis PharmaceuticalsNCT03158311Written as Salmeterol/fluticasone plus tiotropium
- Uncontrolled Lower Respiratory Symptoms in the WTC Survivor ProgramCompletedNot applicableNYU Langone HealthNCT02024204Written as Salmeterol 21mcg for 3 Months
- Study to Compare the Efficacy and Safety of QVM149 With QMF149 in Patients With AsthmaCompletedPhase 3Novartis PharmaceuticalsNCT02571777Written as salmeterol/fluticasone
- The ENERGITO® 2 Study Compares 2 Inhaled Medicines for Chronic Obstructive Pulmonary Disease (COPD). One Medicine is a Combination of Tiotropium and Olodaterol (Stiolto®) Taken Using the Respimat® Inhaler and the Other Medicine is a Combination of Fluticasone and Salmeterol Taken Using the DiskusCompletedPhase 4Boehringer IngelheimNCT03240575Written as Salmeterol
- A Multicenter Randomized 52 Week Treatment Double-blind, Triple Dummy Parallel Group Study to Assess the Efficacy and Safety of QMF149 Compared to Mometasone Furoate in Participants With AsthmaCompletedPhase 3Novartis PharmaceuticalsNCT02554786Written as Salmeterol xinafoate/fluticasone propionate
- Cardiovascular Function in COPD PatientsCompletedPhase 4Boehringer IngelheimNCT03055988Written as Salmeterol
- Evaluation of the Efficacy and Safety of QVA149 (110/50 μg o.d.) vs Tiotropium (18 µg o.d.) + Salmeterol/Fluticasone Propionate FDC (50/500 µg b.i.d.) in Patients With Moderate to Severe COPDCompletedPhase 4Novartis PharmaceuticalsNCT02603393Written as Salmeterol/fluticasone
- Efficacy of FLUTIFORM ® vs Seretide® in Moderate to Severe Persistent Asthma in Subjects Aged ≥12 YearsStatus unknownPhase 3Mundipharma (China) Pharmaceutical Co. LtdNCT03387241Written as fluticasone/ salmeterol
- Effects of Particle Size in Small Airways DysfunctionCompletedPhase 4University of DundeeNCT01892787Written as Salmeterol
- A Study To Investigate The Safety, Toleration And Efficacy of PF00610355 In Chronic Obstructive Pulmonary Disease (COPD) Patients.CompletedPhase 2PfizerNCT00808288Written as Salmeterol
- A Study to Compare the Efficacy of Fluticasone Furoate/Vilanterol Inhalation Powder With Usual Inhaled Corticosteroids (ICS)/Long Acting Beta Agonists (LABA) in Persistent AsthmaCompletedPhase 3GlaxoSmithKlineNCT02446418Written as Salmeterol
- Tiotropium Inhalation Capsules and Salmeterol Inhalation Aerosol on Muscular Efficiency and Resting Energy Expenditure (REE) in Patients With Stable Chronic Obstructive Pulmonary Disease (COPD)CompletedPhase 3Boehringer IngelheimNCT02172794Written as Salmeterol
- Small Airway Function of Fluticasone/Formoterol (Flutiform®) and Fluticasone/SalmeterolTerminatedPhase 4Mundipharma Korea LtdNCT02491970Written as Fluticasone/Salmeterol
- Blacks and Exacerbations on Long Acting Beta Agonists (LABA) vs. Tiotropium (BELT)CompletedPhase 3Brigham and Women's HospitalNCT01290874Written as Salmeterol
- A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol and Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)CompletedPhase 3GlaxoSmithKlineNCT01817764Written as Fluticasone propionate/salmeterol
- Repeat Doses Of A New Medication (GW642444) In Asthmatic PatientsCompletedPhase 2GlaxoSmithKlineNCT00347139Written as Salmeterol 50mcg
- A Study to Evaluate the Efficacy and Safety of Umeclidinium Bromide/Vilanterol Compared With Fluticasone Propionate/Salmeterol Over 12 Weeks in Subjects With Chronic Obstructive Pulmonary Disease (COPD)CompletedPhase 3GlaxoSmithKlineNCT01822899Written as Fluticasone propionate/Salmeterol
Showing 20 of 60.
Codes
What other systems call Salmeterol Xinafoate · ClinicalTrials.gg INT006509
- MeSH (NLM) D000068299Salmeterol XinafoateConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 6EW8Q962A5SALMETEROL XINAFOATEConfirmed FDA, NLM, Wikidata
- RxNorm 72616Confirmed FDA, Wikidata
- Wikidata Q27264747salmeterol xinafoateConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C61935Salmeterol XinafoateOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000068299 | Salmeterol Xinafoate | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 6EW8Q962A5 | SALMETEROL XINAFOATE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 72616 | — | Confirmed FDA, Wikidata |
| Wikidata | Q27264747 | salmeterol xinafoate | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C61935 | Salmeterol Xinafoate | One source FDA |
Also registered as salmeterol (UNII 2I4BC502BT · RxNorm 36117).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.